Clinical Cancer Research, Vol 1, Issue 10 1195-1202, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder

P Allard, Y Fradet, B Tetu and P Bernard
Epidemiology Research Group, Laval University, Saint-Sacrement Hospital, Research Center, 1050 Chemin Sainte-Foy, Quebec G1S 4L8, Canada.

This prospective study was designed to assess the prognostic value of tumor-associated antigens, designated 19A211, M344, T138, and T43, with respect to recurrence of primary superficial bladder cancer. Between September 1990 and April 1992, all patients with primary superficial bladder tumors treated by endoscopic resection in 15 participating hospitals were enrolled. Immunostaining for 19A211 and M344 was performed on paraffin-embedded material, and for T43 and T138 on frozen tissue. Antigenic expression was evaluated blindly by a single pathologist. Patients were followed up with the standard schedule of control cystoscopies. Cox regression was used to estimate hazard ratios (HRs) for first recurrence, and Poisson regression was used to estimate recurrence rate ratios and tumor rate ratios adjusted for primary tumor characteristics. By March 1994, 2254 follow-up cystoscopies had been performed on 368 of the 382 study patients, and tumor recurrence was detected in 55.7% of patients. Positivity to 19A211 was detected in 90% of primary tumors, its expression being associated with a decrease in first recurrence hazard ]HR, 0.65; 95% confidence interval (CI), 0.42-1.03] and in recurrence rate (recurrence rate ratio, 0.70; 95% CI, 0.53-0.92). Positivity to T138 was detected in 15% of tumors, and its expression was associated with an increase in first recurrence hazard (HR, 1.43; 95% CI, 0.92-2.22) and in recurrence rate (recurrence rate ratio, 1.31; 95% CI, 1.00-1.72). Positivity to M344 was detected in 71% of tumors, and its expression was associated with an increase in tumor rate (tumor rate ratio, 1.77; 95% CI, 1.41-1.97). T43 expression was not associated with recurrence end points. In conclusion, recurrence of superficial bladder cancer was associated with antigenic expression of 19A211, T138, and M344, independently of primary tumor characteristics.

This article has been cited by other articles:

				M. Burchardt, T. Burchardt, A. Shabsigh, A. De La Taille, M. C. Benson, and I. Sawczuk Current Concepts in Biomarker Technology for Bladder Cancers Clin. Chem., May 1, 2000; 46(5): 595 - 605. [Abstract] [Full Text] [PDF]

				H. LaRue, P. Allard, M. Simoneau, C. Normand, C. Pfister, L. Moore, F. Meyer, B. Tetu, and Y. Fradet P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers Carcinogenesis, January 1, 2000; 21(1): 101 - 106. [Abstract] [Full Text] [PDF]

				C. Pfister, L. Moore, P. Allard, H. Larue, L. Lacombe, B. Tetu, F. Meyer, and Y. Fradet Predictive Value of Cell Cycle Markers p53, MDM2, p21, and Ki-67 in Superficial Bladder Tumor Recurrence Clin. Cancer Res., December 1, 1999; 5(12): 4079 - 4084. [Abstract] [Full Text] [PDF]

				I. Orlow, H. LaRue, I. Osman, L. Lacombe, L. Moore, F. Rabbani, F. Meyer, Y. Fradet, and C. Cordon-Cardo Deletions of the INK4A Gene in Superficial Bladder Tumors : Association with Recurrence Am. J. Pathol., July 1, 1999; 155(1): 105 - 113. [Abstract] [Full Text] [PDF]

				A. Bergeron, S. Champetier, Hélèn. LaRue, and Y. Fradet MAUB Is a New Mucin Antigen Associated with Bladder Cancer J. Biol. Chem., March 22, 1996; 271(12): 6933 - 6940. [Abstract] [Full Text] [PDF]